Literature DB >> 8626255

Azole drug resistance in yeasts.

E M Johnson1, D W Warnock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8626255     DOI： 10.1093/jac/36.5.751

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  12 in total

1.  Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion.

Authors:  B Beović; T Lejko-Zupanc; J Pretnar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

2.  Trends in antifungal susceptibility among Candida sp. Urinary isolates from 1994 and 1998.

Authors:  J Baran; E Klauber; J Barczak; K Riederer; R Khatib
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United kingdom mycology reference laboratory.

Authors:  Christopher J Linton; Andrew M Borman; Grace Cheung; Ann D Holmes; Adrien Szekely; Michael D Palmer; Paul D Bridge; Colin K Campbell; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

4.  Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.

Authors:  P Marichal; J Gorrens; L Laurijssens; K Vermuyten; C Van Hove; L Le Jeune; P Verhasselt; D Sanglard; M Borgers; F C Ramaekers; F Odds; H Vanden Bossche
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Prospective study of Candida species in patients at a comprehensive cancer center.

Authors:  A Safdar; V Chaturvedi; E W Cross; S Park; E M Bernard; D Armstrong; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.

Authors:  G P Moran; D J Sullivan; M C Henman; C E McCreary; B J Harrington; D B Shanley; D C Coleman
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans.

Authors:  M A Tornatore; G A Noskin; D M Hacek; A A Obias; L R Peterson
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

8.  Rapid molecular identification of pathogenic yeasts by pyrosequencing analysis of 35 nucleotides of internal transcribed spacer 2.

Authors:  Andrew M Borman; Christopher J Linton; Debra Oliver; Michael D Palmer; Adrien Szekely; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2010-08-11       Impact factor: 5.948

9.  Susceptibility profile of vaginal yeast isolates from Brazil.

Authors:  M A Ribeiro; R Dietze; C R Paula; D A Da Matta; A L Colombo
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

Review 10.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.